FLT3LG and acute myeloid leukemia: Moreover, in a phase I trial (NCT01811992), GS‐3583 (FLT3L‐Fc) was well tolerated but resulted in fatal acute myeloid leukemia (AML) in a patient with preexisting clonal hematopoiesis, underscoring the need for caution in patient selection.